1.. Introduction {#sec1}
================

Using the premise that effective variants are in linkage disequilibrium (LD) with common polymorphisms and haplotypes, linkage and association studies have identified genes involved in the development of traits and pathologies. Upon their identification, the regions flanking associated markers are sequenced to find the linked, penetrant variant. However, rare variants are often not detectable using LD-based methods. This problem has been alleviated by recent advances in next-generation sequencing (NGS), and the detection of highly penetrant rare variants associated with disease has reduced the heritability gap for such diseases as autism, Crohn\'s disease and osteoporosis (Kosmicki *et al.*, [@ref18]; Bomba, *et al.* [@ref7]). Despite these advances, for most traits and complex disorders the underlying genes and variants remain elusive.

Recessive disorders are caused by mutations in both copies of a gene. The mutations may be homozygous, that is, identical or compound heterozygous. Compound heterozygous (CH) variants are two different variants in a gene on opposite alleles of a chromosome and it is speculated that CH mutations account for many recessive diseases (Li *et al.*, [@ref21]; Sanjak *et al.*, [@ref29]). Lack of detection of CH variants may explain a significant portion of missing heritability for all phenotypes (Li *et al.*, [@ref21]; Zhong *et al.*, [@ref37]; Sanjak *et al.*, [@ref29]). Association studies using polymorphisms are LD-based and recent association studies using rare variants compare total variant burden between cases and controls to account for the contributions of multiple alleles at a locus to phenotype. Importantly, because LD-based studies require recessive variants to be on the same genetic background and total variant burden analyses are not allele specific, neither discerns between dominant and recessive models of inheritance.

Burden tests may account for compound heterozygosity if the variants are allocated to one of the two alleles for a gene, that is, phased. Relatively common variants may be phased assuming linkage to surrounding haplotypes; in families, rare variants are phased using parental genotypes. Once variants are phased, it may be determined if an individual\'s variants are on different chromosomes, and burden tests that aggregate using an indicator function (i.e. presence of qualifying variants) may assess enrichment for recessive variants.

Here we provide a publicly available tool, VarCount, that is user-friendly and effective for researchers seeking to quantify the presence or absence of a variant or variants in a gene at the individual level. VarCount is useful for the quantification of heterozygous, homozygous or CH variants per sample. We used VarCount to query the Epi4k (Epi4k Consortium *et al.*, [@ref14]) dataset for rare homozygous and CH variants and found enrichment for rare, CH variants in six genes, including three involved in neuronal development or growth (*PRTG*, *TNC* and *MACF1*). The variants in the 1000 Genomes Project database are now phased (1000 Genomes Project Consortium *et al.*, [@ref1]; [@ref2]; [@ref3]), and so genes may be queried for *in trans* combinations of variants. The Epi4k enrichment was identified in comparison to the 1000 Genomes Project participants combining all ancestries and considering only individuals of European ancestry.

2.. Materials and methods {#sec2}
=========================

Processing of Epi4k vcf files

The Epi4k data (Epi4k Consortium *et al.*, [@ref14]) were accessed by permission via the Database of Genotypes and Phenotypes (dbGaP Study Accession, phs000653.v2.p1). Individual vcf files were combined using the CombineVariants function in GATK (McKenna *et al.*, [@ref23]). The vcf files were then annotated with minor allele frequencies (MAFs) from EVS (Exome Variant Server, NHLBI GO Exome Sequencing Project \[ESP\], Seattle, WA \[URL: <http://evs.gs.washington.edu/>[EVS/](EVS/)\]), 1000 Genomes Project and ExAC (Lek *et al.*, [@ref20]), and with information regarding the effect of each variant using SNPSift/SNPEff (Cingolani *et al.*, [@ref8]). The databases used for annotation were dbNSFP2.9 (for MAF and CADD score) and GRCh37.75 for protein effect prediction. SNPSift was used to remove any variants not inducing a protein-changing event (not 'HIGH' or 'MODERATE' impact) based on SNPEff annotation -- this includes missense, nonsense, splice-site and insertion/deletion variants. Variants with quality flags and multiallelic variants, that is, those with more than two known nucleotide values, were also removed. Variants remaining after filtering were cross-referenced with the 1000 Genomes Project variants from the same MAF threshold to ensure that any variants removed from one dataset were removed from the other. The annotated vcf was used as input for VarCount. Ancestry for each exome was determined using LASER (Wang *et al.*, [@ref33]) and this information was input to VarCount via the SampleInfo.txt file. Ancestry and phenotype information for each proband are described in Supplementary Table 1. In addition to the annotated vcf file, the parameters.txt and subjectinfo.txt (containing sex and ancestry information) were used as input. Within the parameters file, the following qualifications were selected: (1) counting at the transcript (rather than gene) level, (2) protein-changing effects, (3) MAF threshold of either 0.005 or 0.01, (4) all within-dataset and annotated (1000 Genomes Project, ExAC and EVS) MAFs, and (5) either CH or homozygous variants. Analyses were run separately for the two MAFs and using all Epi4k probands (264) and only those of European ancestry (207). Because the variants were not phased, VarCount was used to query the vcf file for individuals with two or more variants in each transcript. The output, a list of counts for each transcript was then used to query the parental vcf files for genotype information to determine which sets of variants composed *in trans* combinations of variants. Final counts were determined using parental genotype information. Custom python scripts were used to query for parental genotypes and to count true compound heterozygotes or homozygotes. *De novo* variants were excluded in the determination of true *in trans* variants. Processing of 1000 Genomes Project vcf files

Vcf files for the 2504 participants in the 1000 Genomes Project (1000 Genomes Project *et al.*, [@ref3]) were downloaded by chromosome from the 1000 Genomes Project [ftpsite](ftpsite). To reduce input file size, the genomic regions for the hg19 mRNA transcripts were downloaded via UCSC\'s Table Browser and used to remove noncoding regions from the vcf files. Including all exons from UCSC allowed for a more conservative analysis, given that the Epi4k data were sequenced using various exome captures, which are not inclusive of all possible exons. The variants were annotated and filtered via the same steps as the Epi4k vcf file. Multi-allelic variants were also removed prior to analysis by VarCount. A diagram showing the steps involved in processing and analysing the variant files is shown in ([Figure 1](#fig01){ref-type="fig"}). Fig. 1.Flow diagram for the processing and analysis of variant lists. Vcf files are annotated and filtered using SNPSift/SNPEff. Final vcf along with parameter and sample information files are input to VarCount. The input files are processed to recode minor and major alleles when the MAF \>0.5 and to count the number of individuals with variants qualifying based on information in the parameter file. The final output lists for every transcript or gene, the number of individuals with qualified variants in that locus (counts.text), which individuals have the variant(s) (countfile.txt), and which variants are harboured by each individual (output.txt).

Vcf files were queried for homozygous and CH variants using VarCount. Because the variants in the 1000 Genomes Project vcf files are phased, determining true compound heterozygotes is automatic using VarCount. In addition to the annotated vcf file, the parameters.txt and subjectinfo.txt (containing sex and ancestry information) were used as input. Within the parameters file, the same qualifications used in the Epi4k analysis were selected: analyses were run for each of the two MAFs (0.5 and 1.0%) and for all 1000 Genomes Project participants and using only those of European (EUR) ancestry. The final output from analyses was for each MAF cutoff and for each population, counts for every transcript in which at least one individual harboured recessive variants. Epi4k statistical analysis

Using R statistical software, a Fisher\'s exact test was used to detect transcripts with significant differences in the proportion of individuals with homozygous or CH variants between the Epi4k dataset and the 1000 Genomes Project dataset. Odds ratios and p-values were calculated using the number of individuals with and without qualifying variants. Analyses were performed using all ancestries, and for only individuals of European ancestry. Both Bonferroni and Benjamini-Hochberg adjustments were used to determine significance thresholds after correction for multiple testing. The number of tests was based on the number of transcripts with at least one individual in either the Epi4k or 1000 Genomes Project dataset with *in trans* coding variants with MAFs below the set threshold. Structural modelling of PRTG

The three-dimensional structure of Protogenin (PRTG) was modelled off the crystal structure of the human receptor protein tyrosine phosphatase sigma (PDB: 4PBX; 25.1% sequence identity) using MODELLER 9.14 (Webb and Sali, [@ref34]). The resultant model superimposed with the template had an RSMD of 4.94 Å over 442 C*α* atoms. Charges and hydrogen atoms were added to the wild-type and mutant FGR models using PDB2PQR (Dolinsky *et al.*, [@ref13]). Electrostatic potentials were calculated using APBS (Konecny *et al.*, [@ref17]) as described previously (Moshfegh *et al.*, [@ref26]; Cox *et al.*, [@ref10]; Toral *et al.*, [@ref30]). Protein and solvent dielectric constants were set to 2.0 and 78.0, respectively. All structural figures were generated by PyMOL (<https://pymol.org/2/>; Schrödinger, LLC).

3.. Results {#sec3}
===========

Varcount: variant quantification at the individual level

Varcount is a free, open source tool useful for the quantification of heterozygous, homozygous or CH variants per sample. Input variants may be phased or unphased. All python scripts and supporting files may be downloaded from Github at <https://github.com/GeneSleuth/VarCount>. Supporting files include the 'parameters.txt' file where the user may select variant filters for variant effect, MAF and inheritance pattern (homozygous, CH, one variant or two variants), and sample filters based on information entered into the 'SampleInfo file'. Input vcf files must be annotated with SNPSift/SNPEff using the dbNSFP and GRCh37/38 databases. A readme file with instructions is also provided. A flow diagram with the steps involved in processing of data is depicted in [Figure 1](#fig01){ref-type="fig"}. CH variants in Epi4k probands reveal novel epilepsy genes

We used VarCount to query the Epi4k dataset for rare homozygous and CH variants. The Epi4k data are whole exome data from 264 trios with a child affected by epileptic encephalopathy, either infantile spasms (IS) or Lennox-Gastaut Syndrome (LGS) (Epi4k Consortium et al., [@ref14]). Counts were performed using individuals of all ancestries or just those of European ancestry (207/264). Individuals from the 1000 Genomes Project were used as controls. The individual counts and p-values for the analyses are listed in (Supplementary Tables 2--5). Including only rare variants (MAFs below 0.5 and 1.0%) determined enrichment for CH variants in six genes. For combined ancestries, the six genes are in order of significance: *OSBP2*, *PRTG*, *ABCC11*, *MACF1*, *STAB1* and *TNC*. *PRTG* and *TNC* were also highly ranked in the 1% MAF analysis, with one additional count for each transcript. Variants for all six genes are listed in [Table 1](#tab01){ref-type="table"}. In our analysis of just individuals of European ancestry, *MACF1* was the most significantly enriched gene using a 0.5% MAF. The p-values indicated in [Table 1](#tab01){ref-type="table"} are for individual tests; there were no p-values significant after correction for multiple testing. Table 1.Rare (\<0.5 and 1.0% minor allele frequency) compound heterozygous variants in Epi4k participants.GeneTranscriptSexPhen^a^.Anc^b^.Chr:bp\*dbSNP IDREF/ ALTExac\
ALL AF^c^ExAC\
NFE AFPeptide changeEpi4k \# (1%)1 kg \# (1%)p-valueEpi4k \# (0.5%)1 kg \# (0.5%)p-valueEU (y/n)^d^: All (y/n)EU (y/n): All (y/n)EU:AllEU (y/n): All (y/n)EU (y/n): All (s/n)EU:All*PRTG*ENST000\
00389286FISEU15:56032666rs373423650T/C9.94E-051.65E-04E104G3/204: 3/2610/503: 0/2504**0.0245: 0.00086**2/205: 2/2620/503: 0/25040.0847: **0.0091**15:56032666rs185716584C/G0.0030220.004315E104DMLGSEU15:56032665rs372777171C/A8.28E-061.50E-05E575\*15:55965698rs185716584C/G0.0030220.004315E104DMLGSEU15:56032665rs35718474G/A0.0030330.006701P13S15:56035093rs148011047T/G0.0026110.003608K977T*OSBP2*ENST000\
00332585MISEU15:55916703rs200118898C/G1.09E-041.98E-04S143W2/205: 2/2620/503: 0/25040.0847: 0.00912/205: 2/2620/503: 0/25040.292: **0.0091**22:31091324rs201298398G/A3.20E-045.19E-04R262QMLGSE Asia22:31137288rs576508023G/C8.42E-060G115R22:31091239NAC/T1.66E-050R383W*ABCC11*ENST000\
00394747FISEU22:31283452rs529824818C/T8.24E-060C543Y2/205: 2/2620/503: 2/25020.0847: 0.04782/205: 2/2620/503: 1/25020.0847: 0.025516:48242388rs199839251C/T8.29E-061.51E-05E273KMLGSEU16:48250159NAC/ANANAR889M16:48226471NAC/ANANAG636V*TNC*ENST000\
00345230MISEU16:48234362rs200401362C/T8.24E-060G861R2/205: 3/2610/503: 4/25000.0847: 0.0221/206: 2/2620/503: 2/25020.29: 0.04789:117840315rs117058692C/G7.77E-040.001248G171R9:117849499rs143586851C/T2.23E-043.90E-04A39TMISC/S Asia9:117853183rs149986851C/A2.06E-043.75E-04G203V9:117849402rs139280264G/A8.51E-040.001247R1066CMISEU9:117835900rs371055558C/T2.54E-053.07E-05G576S9:117848284rs144032672C/T0.0013360.002026G210S*MACF1*ENST000\
00289893MISEU9:117849382NAG/A1.65E-053.00E-05R4344Q3/204: 3/2611/502: 11/24930.0769: 0.1423/204: 3/2610/503: 6/2498**0.0245**: 0.04781:39900231rs141949859G/T6.34E-041.12E-03V3535FMISEU1:39853797rs145271544G/TNANAA3264S1:39852984rs138819868T/G2.46E-033.85E-03F5885LMLGSEU1:39951304NAA/G8.28E-060I1066V1:39800136NAG/C8.2641.50E-05W4967C*STAB1*ENST000\
00321725MISME1:39910474rs145751447G/A9.17E-050D1289N0/207: 2/2621/502: 6/24980.99: 0.1730/207: 2/2621/502: 2/25020.99: 0.04783:52549439rs147953260G/A0.0015120.002524R1872HFISC/S Asia3:52554531rs189303343A/G4.05E-053.66E-05I590V3:52540204NAC/TNANAR2351W[^1][^2][^3][^4]

The variants for the three individuals with CH *PRTG* variants are depicted in [Figure 2a](#fig02){ref-type="fig"}. Because of the concentration of variants at position E104, we performed structural modelling to predict the pathogenicity of the PRTG variants. The p.Glu104Gly and p.Glu104Asp variants localize to the immunoglobulin (Ig)-like domain 1 ([Figure 2a](#fig02){ref-type="fig"}). Ig-like domains are responsible for mediating protein--protein and protein--peptide interactions. The p.Glu104Gly disrupts a negative charge in the Ig-like 1 domain. This loss of charge may disrupt interactions with putative PRTG-binding partners ([Figure 2c](#fig02){ref-type="fig"}). Fig. 2.PRTG compound heterozygous mutations in Epi4k probands. (a) Theoretical model of the human PRTG structure spanning the plasma membrane indicating mutation locations in each child. The three pairs of *in trans* mutations, indicated in red, were found using a \<1% MAF threshold. (b) Schematic representation of PRTG functional domains. Multiple sequence alignment of the PRTG Ig-1 domain. The E104 residue is 100% conserved across seven species. (c) Top: Electrostatic potential surface of PRTG calculated in APBS. Bottom: Close-up of the PRTG electrostatic potential surface at the site of mutation. The p.Glu104Gly mutation leads to a loss of negative charge, which may disrupt interactions with putative PRTG binding partners. The p.Glu104Asp mutation does not lead to a change in charge or electrostatic potential.

The *de novo* variants identified by Epi4k Consortium and the Epilepsy Phenome/Genome Project (Epi4k Consortium *et al.*, [@ref14]) in the nine probands with either *PRTG*, *TNC* or *MACF1* recessive variants are described in [Table 2](#tab02){ref-type="table"}. For the three patients with CH *PRTG* variants, one patient harbours a *de novo* missense variant in *HSF2*, the second has a nonsense variant in *CELSR1*, and the third patient has two *de novo* variants -- a missense in Fam102A and a 3´UTR variant in *USP42*. *De novo* mutations were only reported in one of the probands with *in trans TNC* variants -- a missense variant in *DIP2C* and a splice donor change in *IFT172*. All three patients with CH variants in *MACF1* were reported to have *de novo* mutations. The first patient has a 5´ and 3´UTR *de novo* variant in *FAM19A2* and *GLRA2*, respectively, and the second patient also has a 3´UTR *de novo* change in the gene *LRRC8D* and a missense change in *SNX30*. One *de novo* variant was identified in the third proband in the gene *FAM227A.* Polyphen2 categories and CADD scores for each *de novo* variant as well as missense and loss-of-function constraint metric values for each gene (from ExAC) are also listed in [Table 2](#tab02){ref-type="table"}. The z-score is a ratio of expected to identified missense variants in a particular gene, and pLI is a gene\'s probability of being loss-of-function intolerant. These constraint metrics are calculated using genomic data from controls without severe genetic diseases in the ExAC database (Lek *et al.*, [@ref20]). Table 2.*De novo* variants in Epi4k probands with compound heterozygous variants in *PRTG*, *TNC* or *MACF1*.GeneMissense z-score^a^pLI^b^CH variantsSexPhenotypegene w/ *de novo*Variant typePolyphen-2^c^CADD^d^Missense z-score^a^pLI^b^*PRTG*--0.920.02E104G, E104DFIS*HSF2*MissenseP241.770.93*PRTG*E104D, E575XMLGS*CELSR1*Stop-gainedNA354.421.00*PRTG*P13S, K977TMLGS*FAM102A*MissenseD25.11.800.43*USP42*3´ UTRNA--0.691.00*TNC*--0.140.00G861R, G171R, A39TMIS*DIP2C*MissenseB23.65.821.00*IFT172*Splice donorNA23.90.220.00*TNC*G203V, R1066CMISNA----------*TNC*G576S, G210SMISNA----------*MACF1*2.631.00R4344Q, V3535FMIS*FAM19A2*5´ UTRNANA1.110.55*GLRA2*3´ UTRNANA3.280.91*MACF1*A3264S, F5885LMIS*LRRC8D*3´ UTRNANA2.700.87*SNX30*MissenseB17.90.900.97*WDFY2*SynonymousNANA1.150.00*MACF1*I1066V, W4967CMLGS*FAM227A*MissenseP9.4NANA[^5][^6]

4.. Discussion {#sec4}
==============

Epileptic encephalopathies are a group of severe, early-onset seizure disorders with consistent EEG abnormalities that over time interfere with development and cause cognitive decline (Covanis, [@ref9]). The Epi4k dataset contains exome sequences from 264 trios that include a proband with epileptic encephalopathy, either LGS or IS. LGS is characterized by frequent, mixed epileptic seizures that arise most frequently between the ages of 3 and 5 (Amrutkar & Riel-Romero, [@ref6]). IS occurs during the first year of life and is cryptic in its presentation, with mild head bobbing and is often not detected until the seizures have caused significant neurological damage (Kossoff, [@ref19]). IS often progress into LGS over time.

We developed a free and user-friendly tool, VarCount, to query vcf files for individuals harbouring variants that qualify according to user specification. To test its function, we used VarCount to quantify rare, CH variants in probands from the Epi4k trio dataset and found enrichment for variants in six genes including *PRTG*, *TNC* and *MACF1*. *PRTG* codes for protogenin, a member of the immunoglobulin superfamily that is involved in axis elongation and neuronal growth during early vertebrate development (Toyoda *et al.*, [@ref31]; Vesque *et al.*, [@ref32]). TNC and MACF1 are also directly involved in neuronal development and/or growth. TNC (Tenascin-C) is an extracellular matrix glycoprotein involved in axonal growth and guidance (Jakovcevski *et al.*, [@ref15]). Seizures up-regulate *TNC* in the hippocampus, and in a pilocarpine epilepsy model up-regulation was shown to be mediated by TGF-*β* signalling (Mercado-Gomez *et al.*, [@ref24]). MACF1 is a cytoskeletal crosslinking protein highly expressed in the brain and is crucial for neuron development and migration (Moffat *et al.*, [@ref25]). *MACF1* variants are associated with the neurological pathologies Parkinson\'s disease, autism and schizophrenia (Moffat *et al.*, [@ref25]). Recently, highly penetrant *de novo MACF1* mutations were identified in several patients with a newly characterized lissencephaly with a complex brain malformation (Dobyns *et al.*, [@ref11]). This new phenotype highlights *MACF1* variants' variable impact on disease pathogenesis. Given both the enrichment in Epi4k probands for CH variants in these genes as well as their known involvement in neuronal processes, we suggest that *PRTG*, *TNC* and *MACF1* are candidate recessive epilepsy genes.

The primary publication reporting analysis of the Epi4k trio dataset was a description of *de novo* mutations in the probands (Epi4k Consorium *et al.*, [@ref14]). An analysis of CH variants was also reported, using a MAF cutoff of 0.15%, which is lower than the cutoff used in the work presented here. In this analysis, the parents were used as internal controls, and CH variants in 351 genes were identified, without genome-wide significance. The authors only listed five of the genes which are known to cause Mendelian disorders that include a seizure phenotype -- *ASPM*, *CNTNAP2*, *GPR98*, *PCNT* and *POMGNT1*. In our analysis using the 1000 Genomes Project participants as controls, enrichment for CH variants was not detected in any of these genes. Using the number of individuals with *in trans* variants in a gene (transcript) as an indicator function required at least two probands to have qualifying variants in order to detect single-test significance, with complete absence of qualifying variants in controls. It is clear from the analyses using either internal controls or the 1000 Genomes Project as controls that a larger sample size is required to achieve genome-wide significance.

The *de novo* variants reported by the Epi4k Consortium and the Epilepsy Phenome/Genome Project (Epi4k Consortium *et al.*, [@ref14]) in the nine probands with CH variants in *PRTG*, *TNC* or *MACF1* are described in [Table 2](#tab02){ref-type="table"}. Of the 12 genes with *de novo* variants identified in the nine patients, three are implicated in neurological disease. *CELSR1* is a planar cell polarity gene in which mutations are known to cause neural tube defects including spina bifida (Robinson *et al.*, [@ref28]). *De novo* deletions of *DIP2C* have been reported in two patients with cerebral palsy, one of whom also had ADHD, and the other had seizures in infancy (Zarrei *et al.*, [@ref35]). In another report, deletions including *DIP2C* and/or *ZMYND11* were identified in several patients with developmental delay including three patients with seizures (DeScipio *et al.*, [@ref12]). GLRA2 is a glycine receptor involved in neurodevelopment in which variants are implicated in autism (Pilorge *et al.*, [@ref27]; Lin *et al.*, [@ref22]), including a patient with comorbid epilepsy (Zhang *et al.*, [@ref36]).

Of the *de novo* variants reported in these genes, the nonsense variant in *CELSR1* identified in one of the probands with *in trans PRTG* variants is the most likely to be pathogenic. However, regarding their involvement in neural tube defects, variants in *CELSR1* are thought to contribute to pathogenesis but not in a Mendelian fashion, as variants have been found to be inherited from unaffected parents or to be ineffective in functional assays (Robinson *et al.*, [@ref28]; Allache *et al.*, [@ref5]). The nonsense *CELSR1* variant in the patient reported here may contribute to epilepsy in the presence of a genetic modifier. The *de novo* missense mutation in *DIP2C* is predicted to be deleterious (CADD = 23.6) and has a low rate of benign missense variation based on constraint metrics (z = 5.82). The *de novo* variant in *GLRA2* is in the 3´UTR so it is difficult to predict its impact on gene function and subsequent pathogenicity.

The CH variants in *PRTG*, *TNC* and *MACF1* are similarly variable in predicted pathogenicity, with CADD scores ranging from between less than one to 38. *PRTG* and *TNC* both have constraint metrics indicative of a high tolerance to both missense and loss-of-function variants, while *MACF1* is moderately intolerant of missense variants (z = 2.63) and extremely intolerant of loss-of-function variants (pLI = 1.0). Interestingly, aside from the 3´UTR variant in *GLRA2*, none of the *de novo* variants in the Epi4k participants with *MACF1* CH variants are in genes associated with neurological disease or predicted with confidence to have a negative impact on gene function. This, in addition to *MACF1*'s intolerance to missense or nonsense variants, is supportive of the pathogenicity of the biallelic variants in the gene.

In summary, we present a free tool VarCount for the quantification of qualifying variants as an indicator function per individual in the analysis of variant lists (vcf files). We used VarCount to assess enrichment of rare, coding, CH variants in a cohort of 264 epilepsy probands and found enrichment in three genes involved in neurodevelopmental processes -- *PRTG*, *TNC* and *MACF1*. A missense change at the E104 residue of PRTG was identified three times in two different probands. Significance was not maintained after correction for multiple testing, and larger cohorts or candidate gene studies using a different sample set are necessary to validate this enrichment. In the context of the *de novo* mutations also present in these patients, experimentation is necessary in order to delineate if the CH or *de novo* variants, or both, are pathogenic in the development of epileptic encephalopathy. *PRTG*, *TNC* and *MACF1* are candidate recessive epilepsy genes and our work highlights that inheritance of CH variants should not be excluded from gene discovery or diagnostic analyses of patients with epilepsy.
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[^1]: ^a^Phen = phenotype, ^b^Anc = ancestry, ^c^AF = allele frequency, ^d^y/n corresponds to yes/no counts of individuals with qualifying variants.

[^2]: \*bp (base pair position) in hg19/Build37.

[^3]: Ancestries: EU = European, E Asia = East Asia, C/S Asia = Central/South Asia, ME = Middle East. Phenotypes: IS = Infantile spasms, LGS = Lennox-Gastaut syndrome.

[^4]: p-values in bold are the most significant for the specific analysis.

[^5]: ^a^z-score is a measure of tolerance to missense variants, based on ratio of expected to identified; ^b^pLI is the probability that a gene is intolerant to loss-of-function variants; ^c^Polyphen2 -- prediction of a missense variant\'s impact on protein structure and function: B = benign, P = possibly damaging, D = damaging (Adzhubei *et al.*, [@ref4]); ^d^CADD = phred-scaled score of Combined Annotation Dependent Depletion, a measure of the deleteriousness of a SNP or INDEL (Kircher *et al.*, [@ref16]).

[^6]: Phenotypes: IS = Infantile spasms, LGS = Lennox-Gastaut syndrome.
